Autres langues NovoCure Limited

Actions

NVCR

JE00BYSS4X48

Temps réel estimé Cboe BZX Autres places de cotation 19:17:21 15/05/2024			Varia. 5j.	Varia. 1 janv.
21,31 ^USD	+4,87 %		+33,66 %	+43,50 %

02/05	Les actions de NovoCure restent stables après avoir annoncé une perte plus faible et un chiffre d'affaires plus élevé au premier trimestre	MT
02/05	BioPharma Credit signe un accord de prêt de 400 millions de dollars avec Novocure Luxembourg	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	02/05
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	02/05
BioPharma Credit agrees USD400 million loan for oncology firm Novacure	02/05
NovoCure: Q1 Earnings Snapshot	02/05
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M	02/05
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon	02/05
Novocure Reports First Quarter 2024 Financial Results	02/05
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Novocure Enters into New Five-Year Up to $400 Million Committed Senior Secured Credit Facility with Funds Managed by Pharmakon Advisors, LP	02/05
NovoCure Limited announced that it expects to receive $400 million in funding	02/05
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024	24/04
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	24/04
NovoCure : Corporate responsibility report	22/04
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024	08/04
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	05/04
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	05/04
Novocure to Report First Quarter 2024 Financial Results	01/04
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs	28/03
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	28/03
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	28/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues NovoCure Limited

Actions

NVCR

JE00BYSS4X48

Autres langues

Filtres